Correction: Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy
Trials. 2022 Oct 5;23(1):852.
doi: 10.1186/s13063-022-06814-8.
1 Newcastle Clinical Trials Unit, 1-4 Claremont Terrace, Newcastle University, Newcastle upon Tyne, NE2 4AE, UK.
2 Brain and Movement Research Group, Clinical Ageing Research Unit, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE4 5PL, UK.
3 Population Health Sciences Institute, Newcastle University, Ridley 1 Building, Newcastle upon Tyne, NE1 7RU, UK.
4 Pharmacy Directorate, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Freeman Road, Newcastle Upon Tyne, NE7 7DN, UK.
5 Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK.
6 NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE1 4LP, UK.
7 Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK. naomi.thomas@newcastle.ac.uk.
8 NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, NE1 4LP, UK. naomi.thomas@newcastle.ac.uk.